Dezocine and Addiction: Friend or Foe?

Bibliographic Details
Title: Dezocine and Addiction: Friend or Foe?
Authors: Childers, Wayne1 (AUTHOR), Elokely, Khaled2 (AUTHOR), Abou-Gharbia, Magid1 (AUTHOR) aboumag@temple.edu
Source: Pharmaceuticals (14248247). Mar2025, Vol. 18 Issue 3, p386. 16p.
Subject Terms: *SEROTONIN transporters, *OPIOID abuse, *TREATMENT of addictions, *BLESSING & cursing, *NEURALGIA, *OPIOID analgesics, *DULOXETINE
Abstract: The neurological effects of opium were first described over 8000 years ago. Morphine was isolated in 1803 and by the mid-1800s had become both a pain-relieving blessing and an addictive curse. As part of the crusade to identify safer and more reliable alternatives to morphine, dezocine (DalganĀ®) was marketed in the US in 1986. Its use was discontinued in the US in 2011 without revealing the reasons, but it remains one of the most widely used analgesic agents in China today. Dezocine's unique pharmacology makes it an effective analgesic with limited opioid-associated side effects and little or no reported potential for dependence and addiction. In addition, dezocine's blocking effect on serotonin and norepinephrine transporters recommends its further exploration as a potential treatment for various chronic and neuropathic pain conditions. Most recently, data suggest that dezocine might represent a viable treatment for addiction management. This report focuses on the data supporting dezocine's non-addictive profile and its potential use to treat opioid addiction and withdrawal, as well as recent efforts to generate formulations of dezocine that support sub-chronic and chronic dosing. [ABSTRACT FROM AUTHOR]
Copyright of Pharmaceuticals (14248247) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
Full text is not displayed to guests.
More Details
ISSN:14248247
DOI:10.3390/ph18030386
Published in:Pharmaceuticals (14248247)
Language:English